Cargando…
Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences
BACKGROUND: Ketamine has recently received considerable attention regarding its antidepressant and anti-suicidal effects. Trials have generally focused on short-term effects of single intravenous infusions. Research on patient experiences is lacking. AIMS: To investigate the experiences over time of...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791565/ https://www.ncbi.nlm.nih.gov/pubmed/33283696 http://dx.doi.org/10.1192/bjo.2020.132 |
_version_ | 1783633621911863296 |
---|---|
author | Lascelles, Karen Marzano, Lisa Brand, Fiona Trueman, Hayley McShane, Rupert Hawton, Keith |
author_facet | Lascelles, Karen Marzano, Lisa Brand, Fiona Trueman, Hayley McShane, Rupert Hawton, Keith |
author_sort | Lascelles, Karen |
collection | PubMed |
description | BACKGROUND: Ketamine has recently received considerable attention regarding its antidepressant and anti-suicidal effects. Trials have generally focused on short-term effects of single intravenous infusions. Research on patient experiences is lacking. AIMS: To investigate the experiences over time of individuals receiving ketamine treatment in a routine clinic, including impacts on mood and suicidality. METHOD: Twelve fee-paying patients with treatment-resistant depression (6 females, 6 males, age 21–70 years; 11 reporting suicidality and 6 reporting self-harm) who were assessed as eligible for ketamine treatment participated in up to three semi-structured interviews: before treatment started, a few weeks into treatment and ≥2 months later. Data were analysed thematically. RESULTS: Most participants hoped that ketamine would provide respite from their depression. Nearly all experienced improvement in mood following initial treatments, ranging from negligible to dramatic, and eight reported a reduction in suicidality. Improvements were transitory for most participants, although two experienced sustained consistent benefit and two had sustained but limited improvement. Some participants described hopelessness when treatment stopped working, paralleled by increased suicidal ideation for three participants. The transient nature and cost of treatment were problematic. Eleven participants experienced side-effects, which were significant for two participants. Suggestions for improving treatment included closer monitoring and adjunctive psychological therapy. CONCLUSIONS: Ketamine treatment was generally experienced as effective in improving mood and reducing suicidal ideation in the short term, but the lack of longer-term benefit was challenging for participants, as was treatment cost. Informed consent procedures should refer to the possibilities of relapse and associated increased hopelessness and suicidality. |
format | Online Article Text |
id | pubmed-7791565 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77915652021-01-15 Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences Lascelles, Karen Marzano, Lisa Brand, Fiona Trueman, Hayley McShane, Rupert Hawton, Keith BJPsych Open Papers BACKGROUND: Ketamine has recently received considerable attention regarding its antidepressant and anti-suicidal effects. Trials have generally focused on short-term effects of single intravenous infusions. Research on patient experiences is lacking. AIMS: To investigate the experiences over time of individuals receiving ketamine treatment in a routine clinic, including impacts on mood and suicidality. METHOD: Twelve fee-paying patients with treatment-resistant depression (6 females, 6 males, age 21–70 years; 11 reporting suicidality and 6 reporting self-harm) who were assessed as eligible for ketamine treatment participated in up to three semi-structured interviews: before treatment started, a few weeks into treatment and ≥2 months later. Data were analysed thematically. RESULTS: Most participants hoped that ketamine would provide respite from their depression. Nearly all experienced improvement in mood following initial treatments, ranging from negligible to dramatic, and eight reported a reduction in suicidality. Improvements were transitory for most participants, although two experienced sustained consistent benefit and two had sustained but limited improvement. Some participants described hopelessness when treatment stopped working, paralleled by increased suicidal ideation for three participants. The transient nature and cost of treatment were problematic. Eleven participants experienced side-effects, which were significant for two participants. Suggestions for improving treatment included closer monitoring and adjunctive psychological therapy. CONCLUSIONS: Ketamine treatment was generally experienced as effective in improving mood and reducing suicidal ideation in the short term, but the lack of longer-term benefit was challenging for participants, as was treatment cost. Informed consent procedures should refer to the possibilities of relapse and associated increased hopelessness and suicidality. Cambridge University Press 2020-12-07 /pmc/articles/PMC7791565/ /pubmed/33283696 http://dx.doi.org/10.1192/bjo.2020.132 Text en © The Author(s) 2020 http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Papers Lascelles, Karen Marzano, Lisa Brand, Fiona Trueman, Hayley McShane, Rupert Hawton, Keith Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences |
title | Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences |
title_full | Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences |
title_fullStr | Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences |
title_full_unstemmed | Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences |
title_short | Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences |
title_sort | ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences |
topic | Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791565/ https://www.ncbi.nlm.nih.gov/pubmed/33283696 http://dx.doi.org/10.1192/bjo.2020.132 |
work_keys_str_mv | AT lascelleskaren ketaminetreatmentforindividualswithtreatmentresistantdepressionlongitudinalqualitativeinterviewstudyofpatientexperiences AT marzanolisa ketaminetreatmentforindividualswithtreatmentresistantdepressionlongitudinalqualitativeinterviewstudyofpatientexperiences AT brandfiona ketaminetreatmentforindividualswithtreatmentresistantdepressionlongitudinalqualitativeinterviewstudyofpatientexperiences AT truemanhayley ketaminetreatmentforindividualswithtreatmentresistantdepressionlongitudinalqualitativeinterviewstudyofpatientexperiences AT mcshanerupert ketaminetreatmentforindividualswithtreatmentresistantdepressionlongitudinalqualitativeinterviewstudyofpatientexperiences AT hawtonkeith ketaminetreatmentforindividualswithtreatmentresistantdepressionlongitudinalqualitativeinterviewstudyofpatientexperiences |